Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of the American College of Cardiology

Volumn 49, Issue 7, 2007, Pages 753-762

  Ponikowski, Piotr ^a   Anker, Stefan D ^b,c   Szachniewicz, Joanna ^a   Okonko, Darlington ^b   Ledwidge, Mark ^d   Zymlinski, Robert ^a   Ryan, Enda ^d   Wasserman, Scott M ^e   Baker, Nigel ^e   Rosser, Dylan ^e   Rosen, Stuart D ^b   Poole Wilson, Philip A ^b   Banasiak, Waldemar ^a   Coats, Andrew J S ^f   McDonald, Ken ^d  

^a MILITARY HOSPITAL   (Poland)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e AMGEN LTD   (United Kingdom)

^f University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ANEMIA; APPETITE DISORDER; ARTICLE; BREATHING DISORDER; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE INTENSITY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SELF REPORT; SIDE EFFECT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ACTIVITIES OF DAILY LIVING; AGED; ANEMIA; BODY WEIGHT; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, CONGESTIVE; HEMATINICS; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33846936320     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.11.024     Document Type: Article

References (29)

1. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
2. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
3. Sharma R., Francis D.P., Pitt B., Poole-Wilson P.A., Coats A.J., and Anker S.D. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 (2004) 1021-1028
4. Adams K.F., Patterson J.H., Pina I., et al. STAMINA-HFP (Study of Anemia in a Heart Failure Population) registry: rationale, design, and patient characteristics. J Card Fail 9 (2003) S73
5. Felker G.M., Gattis W.A., Leimberger J.D., et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 92 (2003) 625-628
6. Mozaffarian D., Nye R., and Levy W.C. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41 (2003) 1933-1939
7. Kosiborod M., Smith G.L., Radford M.J., Foody J.M., and Krumholz H.M. The prognostic importance of anemia in patients with heart failure. Am J Med 114 (2003) 112-119
8. Szachniewicz J., Petruk-Kowalczyk J., Majda J., et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90 (2003) 303-308
9. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
10. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
11. Witte K.K., Desilva R., Chattopadhyay S., Ghosh J., Cleland J.G., and Clark A.L. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 (2004) 924-930
12. Kalra P.R., Bolger A.P., Francis D.P., et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 91 (2003) 888-891
13. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., and Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
14. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 (2001) 3-10
15. Green C.P., Porter C.B., Bresnahan D.R., and Spertus J.A. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 35 (2000) 1245-1255
16. Rector T.S.K.S., and Cohn J.N. Patients' self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 3 (1987) 198-209
17. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
18. Wilson J.R. Exercise and the failing heart. Cardiol Clin 5 (1987) 171-181
19. Rector T.S., and Cohn J.N. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 124 (1992) 1017-1025
20. Spertus J., Peterson E., Conard M.W., et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 150 (2005) 707-715
21. Samsa G., Edelman D., Rothman M.L., Williams G.R., Lipscomb J., and Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15 (1999) 141-155
22. Rector T.S., Tschumperlin L.K., Kubo S.H., et al. Use of the Living With Heart Failure Questionnaire to ascertain patients' perspectives on improvement in quality of life vs. risk of drug-induced death. J Card Fail 1 (1995) 201-206
23. Bennett S.J., Oldridge N.B., Eckert G.J., et al. Comparison of quality of life measures in heart failure. Nurs Res 52 (2003) 207-216
24. Okonko D.O., and Anker S.D. Anemia in chronic heart failure: pathogenetic mechanisms. J Card Fail 10 (2004) S5-S9
25. Ryan E., Devlin M., Prendiville T., Ledwidge M., and McDonald K. The prevalence and natural history of anaemia in an optimally treated heart failure population. Br J Cardiol 11 (2004) 369-375
26. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
27. Rector T.S., Kubo S.H., and Cohn J.N. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 71 (1993) 1106-1107
28. Berry C., and McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 16 (1999) 247-271
29. Wolfel E.E. Effects of ACE inhibitor therapy on quality of life in patients with heart failure. Pharmacotherapy 18 (1998) 1323-1334